Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Launched by MAYO CLINIC · Feb 14, 2024

Keywords

ClinConnect Summary

The Pancreatic Cancer Detection Consortium (PCDC) is a clinical trial that aims to help detect pancreatic cancer earlier in individuals who are at a higher risk of developing the disease. This study is particularly focused on people who are 50 years or older with a family history of pancreatic cancer or certain genetic mutations, as well as those with specific types of pancreatic cysts that may indicate a higher risk. By identifying these individuals, the trial hopes to find ways to spot pancreatic cancer and other cancers sooner, making treatment easier and more effective.

If you or someone you know has a family history of pancreatic cancer or has been diagnosed with specific high-risk cysts, you might qualify to participate in this study. Participants will undergo various tests and evaluations to help doctors understand how to better detect pancreatic cancer early. It’s important to note that this trial is currently recruiting participants, and those interested should be able to provide informed consent and meet the eligibility criteria. This study could play a crucial role in improving cancer detection and potentially saving lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
• * Age: 50 or older, plus at least one of the following:
• * Mutation unknown or absent:
• • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
• • OR 2+ affected first degree relatives (FDR), defined as blood related parents, siblings, or children)
• * Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
• • CDKN2A/p16, PJS (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
• * OR 1+FDR or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
• • ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
• HIGH-RISK OR WORRISOME PANCREATIC CYSTS:
• • 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
• * High risk stigmata:
• • Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
• • Enhancing mural nodule ≥ 5 mm
• • Main pancreatic duct ≥ 10 mm
• * Worrisome features:
• • Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm
• • Cyst ≥ 3 cm
• • Enhancing mural nodule \< 5 mm
• • Thickened/Enhancing cyst wall
• • Main duct size 5-9 mm
• • Pancreatitis
• • Lymphadenopathy
• • Increased CA 19-9
• • Cyst growth rate ≥ 5 mm /2 years
• Exclusion Criteria:
• • \* Is unable to provide informed consent
• • Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
• • Current or prior history of PDAC or total pancreatectomy
• • Is currently a prison inmate
• • Is not able to speak or read English